Enlivex Ltd.
ENLV
Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with development efforts centered on conditions such as sepsis and osteoarthritis. The company’s current pipeline includes cell-based therapies for immune-related disorders and degenerative joint disease, reflecting its emphasis on novel approaches to immune modulation. Enlivex Ltd. operates from Ness Ziona, Israel, and serves the healthcare and biopharmaceutical markets through research, clinical development, and therapeutic innovation. The company’s role in the market is to advance experimental treatments that address unmet medical needs in inflammation-driven and immune dysregulation conditions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
$1.24B
▲ +8329.2% YoY
Op. Margin
–
ROIC
-1.17%
▲ +41.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +20.0% YoY
Op. Cash Flow (TTM)
-$10M
▲ +18.1% YoY
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$6M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ENLV
Held by ETFs
ENLV is in 1 US ETF. The largest of them, with ENLV's weight in each:
Enlivex (ENLV) in three numbers
Questions about Enlivex
Is Enlivex (ENLV) overvalued?
Enlivex trades at 0.02 times earnings. Intrinsiqq's fair value calculator has no opening value for ENLV, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Enlivex a high-quality business?
Enlivex scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from company filings. Its best check is net debt at -$5M, and its weakest is return on capital at -1.2%. The Quality tab shows every check against its target.
Does Enlivex (ENLV) pay a dividend?
No. Enlivex (ENLV) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ENLV
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.